- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02339935
Improving Hospitalizations for Children With ASD
April 26, 2016 updated by: Kevin Sanders, Vanderbilt University
Improving Hospitalizations for Children With ASD: Testing the Cost and Clinical Efficacy of Integrated Behavioral Intervention
This study aims to implement and test a specific brief Applied Behavior Analysis model for assessing and responding to severe challenging behavior during acute medical and behavioral hospitalization for children with ASD.
The investigators will evaluate the impact of this program by conducting a randomized trial across both medical and psychiatric hospital settings.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
36
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Tennessee
-
Nashville, Tennessee, United States, 37212
- Vanderbilt University Medical Center - MEND Clinic
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
6 years to 18 years (Child, Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- documented diagnosis of an ASD based on clinical DSM-5 diagnostic criteria assessed by attending psychiatrist
- the presence of a significant challenging behaviors (e.g., aggression, property destruction, self-injury, elopement)
- admission to the VPH or medical floors
- individual and caregiver agreement to participate and ability to provide informed consent (and assent).
Exclusion Criteria:
- None
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: ABA Treatment Group
20 Children - 10 hospitalized at Vanderbilt Children's Hospital and 10 hospitalized at Vanderbilt Psychiatric hospital - will receive Brief Analogue Functional Analysis (Brief AFA) targeted to their most problematic behavior(s) while hospitalized
|
The Brief AFA seeks to identify the function of the challenging behavior by creating controlled test conditions in which specific responses are provided for challenging behavior (e.g., attention, escape from task demands, access to tangible - including variants of each as needed), as well as a control condition in which continual access to attention and preferred items is provided.
It consists of a 30-90-minute abbreviated analysis comprised of a single exposure to 2-5-minute test and control conditions, along with replication of applicable test conditions and a treatment probe, which provides evidence of challenging behavior function faster than other methods.
|
|
Other: Control Group
20 Children - 10 hospitalized at Vanderbilt Children's Hospital and 10 hospitalized at Vanderbilt Psychiatric hospital - will receive all typical standard of care procedures while hospitalized, but will not receive Brief AFA
|
These participants will receive typical standard of care procedures while hospitalized, but will not receive the additional behavioral intervention
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Aberrant Behavior Checklist
Time Frame: Change from Baseline ABC at Hospital Discharge (an expected average of 42 days) and 3-Months Post-Discharge
|
The ABC is a well-validated measure designed to assess for the presence of clinically significant challenging behavior in the areas of irritability and agitation, lethargy and social withdrawal, stereotypic behavior, hyperactivity and noncompliance, and inappropriate speech.
|
Change from Baseline ABC at Hospital Discharge (an expected average of 42 days) and 3-Months Post-Discharge
|
|
Decrease in Length of Hospitalization
Time Frame: Participants will be followed from admission to discharge, an expected average of 42 days
|
Reduction in the days hospitalized past medical clearance).
|
Participants will be followed from admission to discharge, an expected average of 42 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Clinical Global Impression Scales of Severity
Time Frame: Baseline and Day of Patient's Discharge (an expected average of 42 days from admission)
|
Attending physician's impressions of participant's clinical impairment and improvement.
|
Baseline and Day of Patient's Discharge (an expected average of 42 days from admission)
|
|
Blinded Observational Ratings
Time Frame: Participants will be followed for duration of hospital stay, an expected average of 42 days
|
Blinded coding of the challenging behaviors targeted in the treatment arm
|
Participants will be followed for duration of hospital stay, an expected average of 42 days
|
|
Physician/Nurse/Family Perception of Care
Time Frame: Day of Patient's Discharge (an expected average of 42 days from admission)
|
The primary medical attending, lead discharge nurse staff member, and the child's primary parent will also be asked at discharge to provide both quantitative and qualitative ratings of challenges and successes during hospitalization.
Caregivers will be contacted to complete a simple interview/questionnaire 3- months post-hospitalization regarding changes in the patient's medication, medical conditions, residential/classroom placement, emergency room visits or psychiatric hospitalizations since the discharge date, as well as ratings of successes implementing components of the behavioral strategies plan utilized during the hospitalization (if applicable).
|
Day of Patient's Discharge (an expected average of 42 days from admission)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Kevin Sanders, MD, MEND Clinic - Director
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2015
Primary Completion (Actual)
November 1, 2015
Study Completion (Actual)
November 1, 2015
Study Registration Dates
First Submitted
December 30, 2014
First Submitted That Met QC Criteria
January 15, 2015
First Posted (Estimate)
January 16, 2015
Study Record Updates
Last Update Posted (Estimate)
April 27, 2016
Last Update Submitted That Met QC Criteria
April 26, 2016
Last Verified
September 1, 2015
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 141265
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Autism Spectrum Disorder
-
Fondazione I.R.C.C.S. Istituto Neurologico Carlo...Istituto Clinico HumanitasRecruitingAutism | Autism Spectrum Disorder (ASD) | Autism DisorderItaly
-
The Children's Hospital of Zhejiang University...Not yet recruitingAutism | Autism Spectrum Disorder (ASD)China
-
Poznan University of Physical EducationCompletedAutism | Autism Spectrum Disorder (ASD)Poland
-
Greater Atlanta Integrative PediatricsRecruitingAutism Spectrum Disorder | Autism | ASD | Autism Spectrum Disorder (ASD)United States
-
Adia Med of Winter Park LLCRecruitingAutism Spectrum Disorder | Autism | ASD | Autism Spectrum Disorder (ASD)United States
-
Poznan University of Physical EducationNational Science Centre, PolandCompletedAutism Spectrum Disorder | ASD | Autism Spectrum Disorder High-Functioning | Autism SpectrumPoland
-
Stanford UniversityJohn and Marcia Goldman FoundationNot yet recruitingAutism | Autism Spectrum Disorder (ASD)United States
-
Blinklab LimitedRecruitingAutism Spectrum Disorder | Autism | Neurodevelopmental Conditions | Autism Spectrum Disorder (ASD)United States
-
National Cheng-Kung University HospitalCompletedAutism Spectrum Disorder (ASD) | Autism Spectrum Disorder High-FunctioningTaiwan
-
University of California, Los AngelesUniversity of WashingtonRecruitingAutism Spectrum Disorder (ASD)United States
Clinical Trials on Brief Analogue Functional Analysis
-
National Cancer Institute (NCI)CompletedMale Breast Cancer | Stage IV Breast Cancer | Stage IIIB Breast Cancer | Recurrent Breast CancerUnited States
-
National Cancer Institute (NCI)CompletedChronic Myelomonocytic Leukemia | Recurrent Adult Acute Myeloid Leukemia | Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) | Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) | Adult Acute Myeloid Leukemia With t(8;21)(q22;q22) and other conditionsUnited States
-
Clinic for Orthopedics LovranSpecial Hospital for Orthopedics Biograd na MoruRecruitingTotal Hip Arthroplasty | Functional RecoveryCroatia
-
University Hospital, LilleCompletedHeart Failure | ObesityFrance
-
Ohio State UniversityCompletedAlzheimer Disease, Late OnsetUnited States
-
The University of Hong KongRecruiting
-
Azienda Ospedaliero-Universitaria di ParmaRecruitingLeukemia, Acute Lymphoblastic | Myeloid Leukemia, AcuteItaly
-
T.C. ORDU ÜNİVERSİTESİCompletedHip Dislocation | Hip Osteoarthritis | Total Hip ReplacementTurkey
-
Hacettepe UniversityCompletedScoliosis IdiopathicTurkey
-
National Taiwan University HospitalNational Science Council, Taiwan; National Health Research Institutes, TaiwanUnknownVitiligo | MelanocyteTaiwan